arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Tarsus Pharmaceuticals, Inc.

TARS

$67.55 ▼ -1.52 (-2.20%) at close

9 Visible periods

32 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Tarsus Pharmaceuticals, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.8B

Dividend Yield —

Revenue Growth 146.7% ↘

Op. Margin -15.7% ↗

ROIC -17.6% ↗

FCF / Share $-0.53 ↗

Trailing P/E —

Price / Book 8.4x

FCF Yield —

Debt / Equity 0.21

info Valuation on last close. End-of-day price, Nov 5, 2026.

9-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$451.36M

↑ +146.7% —

Net Income Profit after all expenses

$-66.42M

↑ +42.5% —

Operating Margin Operating profit as % of sales

-15.7%

↑ +76.1% 12th

FCF / Share Free cash flow per share

$-0.53

↑ +76.3% —

Long-Term Debt Long-term obligations

$72.44M

↑ +0.8% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Returns ↓

Financial Health ↑

Cash Quality

Dividend History

Dividend / share · sourced from SEC filings

$0.00 Latest / share

FY 2017

FY 2018

$0.00

FY 2019

$0.00

FY 2020

$0.00

FY 2021

$0.00

FY 2022

$0.00

FY 2023

$0.00

FY 2024

$0.00

FY 2025

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Revenue Growth YoY (%)	146.7% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1734%)	948.6% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+11758%)	-32.4% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-505%)	-54.7% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-784%)	—	—	—	—	—
EPS Growth YoY (%)	48.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	33.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-83.3% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-276.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	84.5% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	42.5% Excellent ↑ Excellent Improving Year-over-year change in net income	15.0% Fair ↑ Fair Improving Year-over-year change in net income	-118.9% Weak ↑ Weak Improving Year-over-year change in net income	-349.1% Weak ↓ Weak Declining Year-over-year change in net income	48.4% Excellent ↑ Excellent Improving Year-over-year change in net income	-474.1% Weak Weak Year-over-year change in net income	-254.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	76.3% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	44.5% Excellent Excellent Year-over-year change in free cash flow	-101.3% Weak Weak Year-over-year change in free cash flow	N/M	N/M	—	—	—	—
Revenue CAGR 3Y (%)	159.5% Excellent Excellent Compound annual revenue growth over 3 years	47.5% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Operating Margin (%) (%)	-15.7% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-205%)	-65.9% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-539%)	—	-242.9% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1719%)	-21.3% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-242%)	—	—	—	—
Effective Tax Rate (%) (%)	-3.2% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.4% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—
Profit Margin (%) (%)	-14.7% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-223%)	-63.2% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-626%)	—	-240.5% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2104%)	-24.2% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-302%)	—	—	—	—
FCF Margin (%) (%)	-4.9% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-46.2% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	—	-191.9% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	5.5% Caution Caution Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	0.34x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	-0.23x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Return on Invested Capital (%)	-17.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-40.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-63.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-29.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-7.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-16.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	56.5% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-12.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-32.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-53.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-27.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-6.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-15.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-7.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-19.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-229%)	-51.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-443%)	-69.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-560%)	-32.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-315%)	-8.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-155%)	-16.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-208%)	77.8% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+418%)	97.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+549%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Debt to Equity (x)	0.21x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-65%)	0.32x Good ↑ Good Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-47%)	0.15x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-75%)	0.10x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-83%)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	—	—	—	—
Interest Coverage (x)	-7.94x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-15.36x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-42.78x Weak Weak Operating income divided by interest expense Optimal: > 5x	-28.52x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—
Net Debt (USD)	$-111.20M	$-22.97M	$-195.13M	$-52.23M	$-171.33M	$-168.13M	$-57.95M	—	—
Debt / EBITDA (x)	-1.03x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.60x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.21x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.31x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—

📊 What does each share earn? 8 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Revenue per Share (USD)	$10.80	$4.87	$0.59	$1.05	$2.77	$0.00	—	—	—
Basic EPS, GAAP (USD)	$-1.59	$-3.07	$-4.62	$-2.52	$-0.67	$-4.32	—	—	—
Free Cash Flow per Share (USD)	$-0.53	$-2.25	$-4.05	$-2.01	$0.15	$-3.48	—	—	—
Dividend per Share (USD)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	—	—
Book Value per Share (USD)	$8.07	$5.85	$5.76	$7.22	$8.06	$8.17	$-2.27	—	—
Tangible Book Value per Share (USD)	$7.90	$5.64	$5.64	$7.22	$8.06	$8.17	$-2.27	—	—
Basic Weighted Avg Shares (shares)	41.78M	37.60M	29.38M	24.62M	20.55M	6.21M	—	—	—
Dividend Payout Ratio (%)	0.0% Excellent → Excellent Stable Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent → Excellent Stable Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent → Excellent Stable Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent → Excellent Stable Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Working Capital (USD)	$387.09M	$276.09M	$219.19M	$209.95M	$164.47M	$165.27M	$57.21M	—	—
LT Debt (USD)	$72.44M	$71.84M	$29.82M	$19.43M	$0.00	—	—	—	—
Total Equity (USD)	$343.43M	$224.53M	$196.99M	$192.90M	$166.73M	$165.98M	$-6.00M	$-1.35M	$-44.00K

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Sales/Revenue/Turnover (USD)	$451.36M	$182.95M	$17.45M	$25.82M	$57.03M	$0.00	—	—	—
Depreciation Expense (USD)	$855.00K	$685.00K	$744.00K	$325.00K	$300.00K	$100.00K	$37.00K	—	—
Net Income, GAAP (USD)	$-66.42M	$-115.55M	$-135.89M	$-62.09M	$-13.83M	$-26.81M	$-4.67M	$-1.32M	—
Operating Cash Flow (USD)	$-12.45M	$-83.03M	$-117.49M	$-49.03M	$3.75M	$-21.14M	$-3.67M	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 9 years · 33 quarters

Tarsus Pharmaceuticals, Inc.

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Dividend History

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare TARS with peers